Literature DB >> 6895874

Comparative quantitative evaluation of hepatic clearance of diethyl-IDA and para-butyl-IDA in jaundiced and non-jaundiced patients.

G L Tarolo, R Picozzi, B Palagi, F Cammelli.   

Abstract

A method for comparative measurement of hepatic clearance of different hepatobiliary agents is described and the clinical use of diethyl-IDA and parabutyl-IDA is discussed. The study was performed with both radiopharmaceuticals in 13 patients with hepatobiliary disease with serum bilirubin ranging from 0.3 to 16.4 mg/100 ml. Diethyl-IDA is preferable for a qualitative evaluation of hepatobiliary disease because of its higher hepatic clearance and faster biliary excretion rate. Parabutyl-IDA is superior for measuring the hepatocytic uptake function, due to the low urinary excretion and the absence of an apparent re-entry from liver to plasma, even in patients with obstructive jaundice. In contrast, an appreciable re-entry can be demonstrated for diethyl-IDA.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6895874     DOI: 10.1007/bf00252666

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  6 in total

1.  The importance of liver uptake and retention indices in assessment of clinical usefulness of hepatobilary imaging agents.

Authors:  H G Reichelt; H I Popescu
Journal:  J Nucl Med       Date:  1979-02       Impact factor: 10.057

2.  Comparison of two different biliary agents in healthy subjects and in patients with liver disease.

Authors:  R Dudczak; K Kletter; P Angelberger; H Frischauf
Journal:  Eur J Nucl Med       Date:  1979-10

3.  Diagnosis of hepatobiliary disease by 99mTc-HIDA cholescintigraphy.

Authors:  L Rosenthall; E A Shaffer; R Lisbona; P Pare
Journal:  Radiology       Date:  1978-02       Impact factor: 11.105

4.  Hepato-biliary scintigraphy and hepatography with Tc-99m diethyl-acetanilido-iminodiacetate in obstructive jaundice.

Authors:  S P Nielsen; J Trap-Jensen; J Lindenberg; M L Nielsen
Journal:  J Nucl Med       Date:  1978-05       Impact factor: 10.057

5.  Experimental and clinical trials of new 99mTc-labeled hepatobiliary agents.

Authors:  B W Wistow; G M Gagne; R W Henderson; J G McAfee; R C Hall; Z D Grossman
Journal:  Radiology       Date:  1978-09       Impact factor: 11.105

6.  The plasma protein binding of HIDA.

Authors:  R W Nicholson; K J Herman; R A Shields; H J Testa
Journal:  Eur J Nucl Med       Date:  1980-08
  6 in total
  5 in total

1.  Pharmacokinetic studies of DISIDA disposition. I. Animal studies.

Authors:  I A Fraser; P Shaffer; J Love; A E Staubus; G Hinkle; J Olsen; L C Carey; P J Fabri; E C Ellison
Journal:  Eur J Nucl Med       Date:  1988

2.  Pharmacokinetic studies of DISIDA disposition. II. Clinical studies.

Authors:  J E Love; P Shaffer; I A Fraser; A E Staubus; J A Lott; G Hinkle; L C Carey; E C Ellison; P J Fabri
Journal:  Eur J Nucl Med       Date:  1988

3.  Cholescintigraphy with 99mTc-diethyl-IDA for the detection of rejection of auxiliary liver transplants in pigs.

Authors:  M W de Jonge; E K Pauwels; P J Hennis; D J Ruiter; C T Koch; J Blom; S W Schalm; J L Terpstra
Journal:  Eur J Nucl Med       Date:  1983

4.  99mTc-diethyl-iodo-HIDA (JODIDA): a new hepatobiliary agent in clinical comparison with 99mTc-diisopropyl-HIDA (DISIDA) in jaundiced patients.

Authors:  R Schwarzrock; J Kotzerke; H Hundeshagen; K Böcker; B Ringe
Journal:  Eur J Nucl Med       Date:  1986

5.  99mTc-diethyl-IDA: the extraction efficiency of the liver.

Authors:  G Galli; P Orlando; P Massari; N Bonifazi; P Magistrelli; R Coppola
Journal:  Eur J Nucl Med       Date:  1983
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.